Andreasen, P.A., Kjoller, L., Christensen, L. and Duffy, M.J. (1997) The urokinasetype plasminogen activator system in cancer metastasis: a review. Int J Cancer, 72: 1-22.
Banerjee, S., Bueso-Ramos, C. and Aggarwal, B.B. (2002) Suppression of 7, 12-dimethylbenz (a)-anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res, 62: 4945-4954.
Barr, R.K. and Bogoyevitch, M.A. (2001) The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol, 33: 1047–1063.
Beaudeux, J.L., Giral, P., Bruckert, E., Foqlietti, M.J. and Chapman, M.J. (2004) Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Cheh Lab Med, 42: 121-131.
Blasi, F. and Carmeliet, P. (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol, 3: 932-943.
Boulton, T.G. and Cobb, M.H. (1991) Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodies. Cell Regul, 2: 357-371.
Brinkman, J.A. and El-Ashry, D. (2009) ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia, 1: 67–78.
Carter, A.B., Knudston, K.L., Monick, M.M. and Hunninghake, G.W. (1999) The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression. J Biol Chem, 274: 30858- 30863.
Chakraborti, S., Mandal, M., Das, S., Mandal, A. and Chakraborti, T. (2003) Regulation of matrix metalloproteinases: An overview: Mol Cell Biochem, 253: 269-285.
Chambers, A.F. and Matrisian, L.M. (1997) Changing views of the role of matrix: metalloproteinases in metastasis. J Natl Cancer Inst, 89: 1260–1270.
Chen, D.H., Shiou, W.Y., Wang, K.C., Huang, S.Y., Shie, Y.T., Tsai, C.M., Shi, J.F. and Chen, K.D. (1999) Chemotaxonomy of triterpenoid pattern of HPLC of Ganoderma lucidum and Ganoderma tsugae. J Chinese Chem Soc, 46: 47-51.
Chen, P.N., Hsieh, Y.S., Chiou, H.L. and Chu, S.C. (2005) Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact, 156: 141–150.
Cheng, W.H., Zheng, X., Quimby, F.R., Roneker, C.A. and Lei, X.G. (2003) Low levels of glutathione peroxidase 1 activity in selenium-deficient mouse liver affect c-Jun N-terminal kinase activation and p53 phosphorlation on Ser-15 in pro-oxidant-induced aponecrosis. Biochem J, 15: 927-34.
Collen, D. and Lijene, H.R. (1991) Basic and clinical aspects of fibrinolysis and thromobolysis. Blood, 78: 3114-3124.
Creemers, E.E., Cleutjens, J.P., Smits, J.F. and Daemen, M.J. (2001) Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure ? Circ Res, 89: 201-210.
Dano, K., Andreasen, P.A., Grondahl-Hansen, K., Kristensen, P., Nielsen, L.S., Skriver, L. (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res, 44: 139-266.
Das, R., Mahadeleshwar, G.H., and Kundu, G.C. (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-Kinase/Akt signaling pathways in breast cancer. J Biol Chem, 278: 28593-28606.
Das, R., Phillip, S., Mahabeleshwar, GH., Bulbule, A. and Kundu, G.C. (2005) Osteopontin: It’s role inregulation of cell motility and nuclear factor kB-mediated urokinase type plasminogen activator expression.IUBMB Life, 57: 441-447.
Denhardt, D.T., Feng, B., Edwards, D.R., Cocuzzi, E.T. and Malyankar, U.M. (1993) Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther, 59: 29-41.
Duffy, M.J., Maguire, T.M., Hill, A., McDermott, E. and O’Higgins, N. (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res, 2: 252–257.
Duffy, M.J. and McCarthy, K. (1998) Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol, 12: 1343–1348.
Egeblad, M. and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2: 161-174.
Eo, S.K., Kim, Y.S., Lee, C.K. and Han, S.S. (1999) Antiherpetic activities of various protein bound polysaccharide isolated from Ganoderma lucidum. J Ethnopharma, 72: 475-481.
Fan, S.Q., Wei, Q.Y., Li, M.R., Zhang, L.Q. and Liang, Q.C. (2003) Expression and clinical significance of MMP-2 and MMP-9, TIMP-1 and TIMP-2 in breast cancer carcinoma.Ai Zheng, 22: 968-973.
Filder, I.J. and Ellis, L.M. (1994) The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79: 185-188.
Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease.Nat Med, 1: 27-31.
Galis, Z.S. and Khatri, J.J. (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res, 90: 251-62.
Gan, K.H., Fann, Y.F., Hsu, S.H., Kuo, K.W. and Lin, C.N. (1998) Mediation of the cytotoxicity of lanostanoids and steroids of Ganoderma tsugae through apoptosis and cell cycle. J Nat Prod, 61: 485-487.
Gomez, D.E., Alonso, D.F. and Yoshiji, H. (1997) Thorgeirsson UP Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol, 74: 111-122.
Greene, J., Wang, M., Liu, Y.E., Raymond, L.A., Rosen, C. and Shi, Y.E. (1996) Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 271: 30375-80.
Guo, Y., Pakneshan, P., Gladu, J., Slack, A., Szyf, M. and Rabbani, S.A. (2002) Regulation of DNA methylatiom in human breast cancer.Effect on the urokinase-type plasminogen activactor gene production and tumor invasion. J Biol Chem, 277: 41571-41579.
Himelstein, B.P., Canete-Soler, R., Bernhard, E.J., Dilks, D.W. and Muschel, R.J. (1994-1995) Metalloproteinase in tumor progration: the contribution of MMP-9. Invasion Metastasis, 14: 246– 258. Review.
Hseu, Y.C., Chang, W.C., Hseu, Y.T., Lee, C.Y., Yech, Y.J., Chen, P.C., Chen, J.Y., and Yang, H.L. (2002) Protection of oxidative damage by aqueous extract from Antrodia camphorata mycelia in normal human erythrocytes. Life Sci, 71: 469-482.
Hseu, Y.C., Yang, H.L., Lai, Y.C., Lin, J.G., Chen, G.W. and Chang, Y.H. (2004) Induction of apoptosis by Antrodia camphorata in human premyelocytic leukemia HL-60 cells. Nutr Cancer, 48: 189-197.
Hseu, Y.C., Wu, F.Y., Wu, J.J., Chen, J.Y., Chang, W.H., Lu, F.J., Lai, Y.C. and Yang, HL. (2005) Anti-inflammatory potential of Antrodia camphorata through inhibition of iNOS, COX-2 and cytokines via the NF-kappaB pathway. Int Immunopharmacol, 5: 1914-25.
Hseu, Y.C., Chen, S.C., Tsai, P.C., Chen, C.S., Lu, F.J., Chang, N.W. and Yang, H.L. (2007) Inhibition of cyclooxygenase-2 and induction of apoptosis in estrogen-nonresponsive breast cancer cells by Antrodia camphorate. Food Chem Toxicol, 45: 1107–1115.
Hseu, Y.C., Chen, S.C., Chen, H.C., Liao, J.W. and Yang, H.L. (2008) Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo. Food Chem Toxicol, 46: 2680–2688.
Hsieh, Y.S., Chu, S.C., Yang, S.F., Chen, P.N., Liu, Y. and Lu, K.H. (2007) Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2.Carcinogenesis, 28: 977-987.
Hsu, L.Y., Kuo, P.L., Cho, Y.C., Ni, W.C., Tzeng, T.F., Ng, L.T., Kuo, Y.H. and Lin, C.C. (2007) Antrodia cinnamomea fruiting bodies extract suppresses the invasive potential of human liver cancer cell line PLC/PRF/5 through inhibition of nuclear factor kB pathway. Food Chem Toxicol, 45: 1249–1257.
Huang, L.C., Huang, S.J., Chen, C.C. and Mau, J.L. (1999) Antioxidant properties of Antrodia camphorata. Proceedings of 3rd International Conference on Mushroom Biology & Mushroom Products. p.275-283.
Huang, S., New, L., Pan, Z., Han, J. and Nemerow, G.R. (2000) Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38a mitogen-activated protein kinase activity. J Biol Chem, 275: 12266–12272.
Huang, G.W., Yang, L.Y. and Lu, W.Q. (2005) Expression of hypoxiainducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol, 11: 1705–1708.
Huang, Q., Shen, H.M. and Ong, C.N. (2004) Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol, 68: 361-371.
Hung, S.H., Shen, K.H., Wu, C.H., Liu, C.L. and Shih, Y.W. (2009) α -Mangostin suppresses PC-3 human prostate carcinoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen expression through the JNK signaling pathway. J Agric Food Chem, 57: 1291–1298.
Johnson, G.L. and Lapadat, R. (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298: 1911-1912.
Karin, M. (1999) The beginning of the end: IκB kinase (IKK) and NF-Κb activation. J Biol Chem, 274: 27339-27342.
Kim, H.W. and Kim, B.K. (1999) Biomedicinal Triterpenoids of Ganoderma lucidum (Aphyllophoromycetideae). Inter J Med Mushrooms, 1: 121-138.
Kim, S., Choi, J.H., Kim, J.B., Nam, S.J., Yang, J.H., Kim, J.H. and Lee, J.E. (2008) Berberine suppresses TNF-α induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. Molecules, 13: 2975-2985.
Knauper, V., Will, H., Lopez-Otin, C., Smith, B., Atkinson, S.J., Stanton, H., Hembry, R.M., and Murphy, G. (1996) Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem, 271: 17124-17131.
Kyriakis, J.M and Avruch, J. (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol, 81: 807-869.Reveiw.
Leber, T.M. and Balkwill, F.R. (1998) Regulation of monocyte MMP-9 production by TNF-a and a tumour-derived soluble factor (MMPSF). Br J Cancer, 78: 724-732.
Lee, C.H., Jeon, Y.T., Kim, S.H. and Song, Y.S. (2007) NF-κB as a potential molecular target for cancer therapy. BioFactors, 29: 19–35.
Lee, S.O., Jeong, Y.J., Kim, M., Kim, C.H. and Lee, S.I. (2008) Suppression of PMA-induced tumor cell invasion by capillarisin via the inhibition of NF-kB-dependent MMP-9 expression. Biochem Biophys Res Commun, 366: 1019–1024.
Lengyel, E., Gum, R., Stepp, E., Juarez, J., Wang, H. and Boyd, D. (1996) Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem, 61: 430-438.
Lev, D.C., Onn, A., Melinkova, V.O., Miller, C., Stone, V., Ruiz, M., McGary, E.C. Ananthaswamy, H.N., Price, J.E. and Bar-Eli, M. (2004) Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol, 22: 2092-2100.
Lin, C.W., Hou, W.C., Shen, S.C., Juan, S.H., Ko, C.H., Wang, L.M. and Chen, Y.C. (2008) Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis, 29: 1807-1815.
Liotta, L.A. (1986) Tumor invasion and metastases – role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Resear, 46: 1–7.
Liu, J. and Lin, A. (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res, 15: 36-42.
McCarthy, K., Maguire, T., McGreal, G., McDermott, E., O’Higgins, N. and Duffy, M.J. (1999) High levels of tissue inhibitor of metalloprotein-1 predict poor outcome in patient with breast cancer. Int J Cancer, 84: 44-48.
McMurtry, V., Simeone, A.M., Nieves-Alicea, R. and Tari, A.M. (2009) Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells. Clin Exp Metastasis, 26: 197–204.
Mizuno, T. (1999) The extraction and development of antitumor-active polysaccharides from medicinal mushrooms in Japan. Inter J Med Mushrooms, 1: 9-29. Review.
Mook, O.R., Frederiks, W.N. and Van, Noorden, C.J. (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta, 1705: 69-89.
Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P. and Aggarwal, B.B. (2001) Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene, 20: 7597-7609.
Nabeshima, K., Inoue, T., Shimao, Y. and Sameshima, T. (2002) Matrixmetalloproteinases in tumor invasion: role for cell migration. Pathol Int, 52: 255– 264.
Nagase, H. (1997) Activasion mechanisms of matrix metalloproteinases. Biol chem, 378: 151-160.
Nakshatri, H., Bhat-Nakshatri, P., Martin, D.A., Goulet, RJJr. and Sledge, GWJr. (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol, 17: 3629-3639.
Nelson, A.R., Fingleton, B., Rothenberg, M.L. and Matrisian, L.M. (2000) Matrix metalloproteinase: biological activity and clinical implications. J Clin Oncol, 18: 1135-1149.
Olson, J.M and Hallahan. A.R. (2004) p38MAPK kinase: aconvergence point in cancer therapy. Trends Mol Med, 10: 125-129. Review.
Ondrey, F.G., Dong, G., Sunwoo, J., Chen, Z., Wolf, J.S., Crowl-Bancroft, C.V., Mukaida, N. and Van Waes, C. (1999) Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NFIL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. MolCarcinog, 26: 119-129.
Parada-Turska, J., Paduch, R., Majdan, M., Kandefer-Szersze, M. and Rzeski, W. (2007) Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol Rep, 59: 233-237.
Park, M.J., Park, I.C., Hur, J.H., Kim, M.S., Lee, H.C., Woo, S.H., Lee, K.H., Rhee, C.H., Hong, S.I. and Lee, S.H. (2002) Modulation of phorbol esterinduced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. J Neurosurg, 97: 112-118.
Patrick, A., Baeuerle, U. and Baltimore, D. (1996) NF-kB: ten years after.Cell, 87: 13-20.
Peng, C.C., Chen, K.C., Peng, R.Y., Chyau, C.C. (2007) Antrodia camphorata extract induces replicative senescence in superficial TCC, and inhibits the absolute migration capability in invasive bladder carcinoma cells. J Ethnopharmacol, 109: 93-103.
Roger, J.D. (1994) MAPKs: new JNK expands the group. TiBS, 19: 470-473.
Rutter, G.A., White, M.R. and Tavare, J.M. (1995) Involvement of MAP kinase in insulin signalling revealed by non-invasive imaging of luciferase gene expression in single living cells. Curr Biol, 5: 890–899.
Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E. and Seiki, M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature, 370: 61-65.
Sato, H. and Seiki, M. (1993) Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene, 8: 395–405.
Sen, R. and Baltimore. (1986) Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a post-translational mechanism. Cell, 47: 921-928.
Shih, Y.W., Shieh, J.M., Wu, P.F., Lee, Y.C., Chen, Y.Z. and Chiang, T.A. (2009) α-Tomatine inactivates PI3K/Akt and ERK signaling pathways in human lung adenocarcinoma A549 cells: Effect on metastasis. Food Chem Toxicol, 47: 1985-1995.
Sliva, D., Rizzo, M.T. and English, D. (2002) Phosphatidylinositol 3-kinase and NF-kB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem, 277: 3150-3157.
Sliva, D. (2004) Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets, 4: 327-336. Review.
Stetler-Stevenson, W.G., Aznavoorian, S. and Liotta, L.A. (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol, 9: 541-573.
Stricklin, G.P. and Welgus, H.G. (1983) Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization. J Biol Chem, 258: 12252-8.
Sturgill, T.W. and Ray, L.B. (1986) Muscle proteins related to microtubule associated protein-2 are substrates for an insulin-stimulatable kinase. BBRC, 134: 565-571.
Turlin, B., Le Quilleuc, D., Leroyer, P., Brissot, P., Deuqnier, Y. and Loreal, O. (2002) High vascular endothelial growth factor (VEGF) expression in chemically-induced hepatic microcancers in mice. J Hepatol, 37: 620-624.
Vassalli, J.D., Sappino, A.P. and Berlin, D. (1991) The plasminogen activator/plasmin system. J Clin Invest, 88: 1067-1072.
Wang, S.Y., Hsu, M.L., Hsu, H.C., Tzeng, C.H., Lee, S.S., Shiao, M.S. and Ho, C.K. (1997) The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages. Int J Cancer, 70: 699-705.
Wasser, S.P. and Weis, A.L. (1999) Medicinal properties of substances occurring in higher basidomycetes mushrooms: current perspectives. Intern J Med Mushrooms, 1: 31-62. Review.
Westermarck, J., Kahari, V.M. (1999) Regulation of matrix metalloprotein expression in tumor invasion. FASEB J, 13: 781-792.
Yan, C., Wang, H. and Boyd, D.D. (2001) KiSS-1 represses 92-kD type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha-induced block of p65/p50 nuclear translocation. J Biol Chem, 276: 1164–1172.
Yang, H.L., Chen, C.S., Chang, W.H., Lu, F.J., Lai, Y.C., Chen, C.C., Hseu, T.H., Kuo, C.T. and Hseu, Y.C. (2006) Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorata.Cancer letters, 231: 215-227.
Yoneda, T., Sasaki, A., Dunstan, C., Williams, P.J., Bauss, F., De Clerck, Y.A. and Mundy, G.R. (1997) Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest, 99: 2509-2517.
Zarubin, T. and Han, J. (2005) Activation and signaling of the p38 MAPK kinase pathway. Cell Res, 1: 11-18.
王伯徹、陳啟楨、華傑。(1998) 食藥用菇類的培養與應用。食品工業發展研究所。p.144-150。江素瑛、吳焜裕、王秋萍、魏逸傑、施睿宏、高尚德以及謝慶良。(2002)樟芝之致基因毒性與抗基因毒性評估。台灣保健食品協會,第二屆第二次年會,大會議程及論文摘要。
江素瑛。(2001)靈芝與樟芝之安全與毒理。「保健食品」跨部會整合推動委員會 p. 64-72。
呂鋒洲。 (2002)牛樟芝各抗腫瘤有效成分的分離、純化,誘發腫瘤凋亡及其作用機轉的研究。十一年度保健食品研究開發計畫成果發表會。p.13-16。
沈立言。(2000)牛樟芝菌絲體發酵萃取液對肝臟生理機能性之影響89年度保健食品研究開發計畫心得發表會。 p.191-198。
李炫璋、莊正宏、蔡金川、黃仕政、陳勁初以及胡淼琳。(2002)中華民國食品科學技術學會。第三十二次(第十六屆第二次)會員大會手冊。 p. 339。
林文鑫、陳俊憲、陳勁初以及呂鋒州。(2000)樟芝液態發酵萃取物對腫瘤細胞株之毒殺性分析。 中華民國食品科學技術學會 第三十次(第十五屆第二次)會員大會手冊。
吳德鵬。 (1995) 樟芝微量成分的研究。國立台灣師範大學化學研究所碩士論文。郭淑卿。(2002) 樟芝發酵液對大鼠肝臟纖維化及胃腸功能之改善作用。中國藥學研究所,碩士論文。陳勁初、林文鑫、陳清農、許勝潔、黃仕政、陳炎煉。(2001)台灣特有真菌-樟芝。
張中姿、陳俊憲、林文鑫、陳勁初以及呂鋒洲。(2001)中華民國食品科學技術學會。第三十二次 (第十六屆第一次)會員大會手冊。 p. 265。
黃鈴娟。 (2000)樟芝與姬松茸之抗氧化性質及其多醣組成分析。國立中興大學食品學系,碩士論文。簡秋源、姜宏哲以及陳淑貞。(1997)牛樟菇培養性狀及其三?衛?成分分析之研究,牛樟生物學及育林技術研討會論文集。林業叢刊第72 號:133-137。
劉翠玲。(2002)樟芝對倉鼠體內脂質代謝與抗氧化狀態之影響。輔仁大學食品營養學系研究所,碩士論文。戴宇昀。(2001)樟芝菌絲體與子實體對四氯化碳及酒精誘導之慢性及急性肝損傷之保肝功能評估. 國立中興大學食品科學系研究所,碩士論文。